NASDAQ:VRDN Viridian Therapeutics (VRDN) Stock Price, News & Analysis $16.66 +0.32 (+1.96%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$16.20▼$17.4750-Day Range$11.60▼$16.6652-Week Range$10.93▼$24.18Volume915,847 shsAverage Volume1.02 million shsMarket Capitalization$1.06 billionP/E RatioN/ADividend YieldN/APrice Target$32.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Viridian Therapeutics alerts: Email Address Viridian Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside92.1% Upside$32.00 Price TargetShort InterestBearish13.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.61) to ($3.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.66 out of 5 starsMedical Sector702nd out of 936 stocksMedical Laboratories Industry16th out of 18 stocks 4.4 Analyst's Opinion Consensus RatingViridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageViridian Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Viridian Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.52% of the outstanding shares of Viridian Therapeutics have been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Viridian Therapeutics has recently increased by 8.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldViridian Therapeutics does not currently pay a dividend.Dividend GrowthViridian Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VRDN. Previous Next 2.4 News and Social Media Coverage News SentimentViridian Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Viridian Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for VRDN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viridian Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.65% of the stock of Viridian Therapeutics is held by insiders.Read more about Viridian Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Viridian Therapeutics are expected to decrease in the coming year, from ($3.61) to ($3.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viridian Therapeutics is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viridian Therapeutics is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViridian Therapeutics has a P/B Ratio of 3.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Viridian Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Viridian Therapeutics Stock (NASDAQ:VRDN)Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.Read More VRDN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRDN Stock News HeadlinesJuly 26 at 6:20 PM | msn.com3 Top Small-Cap Tech Picks for Investors This MonthJuly 26 at 5:51 AM | finance.yahoo.comViridian completes subject enrolment for Phase III trial of TED treatmentJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 25 at 2:46 PM | marketwatch.comViridian Therapeutics Shares Rise on Patient Demand for Thyroid Eye Disease Clinical TrialJuly 25 at 9:46 AM | finance.yahoo.comViridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)July 19, 2024 | markets.businessinsider.comBuy Rating for Viridian Therapeutics on VRDN-001 Clinical Advancements and Market PotentialJuly 8, 2024 | investorplace.com3 Small-Cap Stocks With Explosive 2X Growth PotentialJune 12, 2024 | seekingalpha.comViridian Therapeutics: Key Catalysts Coming In The Second Half Of The YearJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 11, 2024 | businesswire.comViridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye DiseaseMay 31, 2024 | businesswire.comViridian Therapeutics Announces Participation in Upcoming June Investor ConferencesMay 13, 2024 | markets.businessinsider.comViridian Therapeutics (VRDN) Gets a Buy from Stifel NicolausMay 11, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)May 10, 2024 | markets.businessinsider.comAnalyst Issues Buy Rating for Viridian Therapeutics Amid Positive Clinical Progress and Strategic BLA Submission PlanMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics Amidst Accelerated Clinical Progress and Market Expansion PotentialMay 10, 2024 | businesswire.comViridian Therapeutics to Participate in Upcoming May Investor ConferencesMay 10, 2024 | msn.comLadenburg Thalmann Downgrades Viridian Therapeutics (VRDN)May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics on Strong Clinical Trials and Promising Drug ProspectsSee More Headlines Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:VRDN CUSIPN/A CIK1590750 Webwww.viridiantherapeutics.com Phone(617) 272-4600Fax760-537-4101Employees94Year FoundedN/APrice Target and Rating Average Stock Price Target$32.00 High Stock Price Target$40.00 Low Stock Price Target$20.00 Potential Upside/Downside+92.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($4.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-237,730,000.00 Net Margins-75,737.85% Pretax Margin-75,737.85% Return on Equity-92.04% Return on Assets-48.44% Debt Debt-to-Equity Ratio0.05 Current Ratio23.99 Quick Ratio23.99 Sales & Book Value Annual Sales$288,000.00 Price / Sales3,691.93 Cash FlowN/A Price / Cash FlowN/A Book Value$4.48 per share Price / Book3.72Miscellaneous Outstanding Shares63,822,000Free Float63,407,000Market Cap$1.06 billion OptionableOptionable Beta1.12 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Stephen F. Mahoney J.D. (Age 53)MBA, CEO, President & Director Dr. Eric N. Olson Ph.D.Co-Founder & Chairman of Scientific Advisory BoardDr. Michael R. Bristow M.D. (Age 79)Ph.D., Co-Founder & Member of the Scientific Advisory Board Dr. Marvin H. Caruthers Ph.D. (Age 84)Co-Founder & Scientific Advisory Board Member Mr. Vahe Bedian Ph.D.Co-Founder & Scientific AdvisorMr. Seth HarmonSenior VP of Finance and Accounting, Principal Financial & Accounting OfficerMr. Thomas W. Beetham J.D. (Age 54)MBA, Chief Operating Officer Ms. Jennifer Tousignant J.D.Chief Legal OfficerMr. John A. JordanVice President of Investor Relations & Corporate CommunicationsMr. Anthony Casciano (Age 47)Chief Commercial Officer More ExecutivesKey CompetitorsFortreaNASDAQ:FTREVeracyteNASDAQ:VCYTCareDxNASDAQ:CDNAFulgent GeneticsNASDAQ:FLGTCelcuityNASDAQ:CELCView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 56,814 shares on 7/26/2024Ownership: 0.327%AlphaCentric Advisors LLCBought 6,500 shares on 7/26/2024Ownership: 0.020%Hennion & Walsh Asset Management Inc.Bought 69,035 shares on 7/20/2024Ownership: 0.280%SG Americas Securities LLCBought 46,056 shares on 7/12/2024Ownership: 0.072%Kopp LeRoy CBought 205,640 shares on 6/3/2024Ownership: 0.322%View All Insider TransactionsView All Institutional Transactions VRDN Stock Analysis - Frequently Asked Questions How have VRDN shares performed this year? Viridian Therapeutics' stock was trading at $21.78 on January 1st, 2024. Since then, VRDN stock has decreased by 23.5% and is now trading at $16.66. View the best growth stocks for 2024 here. How were Viridian Therapeutics' earnings last quarter? Viridian Therapeutics, Inc. (NASDAQ:VRDN) issued its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.28. The company's revenue was down 26.5% compared to the same quarter last year. Who are Viridian Therapeutics' major shareholders? Top institutional shareholders of Viridian Therapeutics include Bank of New York Mellon Corp (0.33%), Hennion & Walsh Asset Management Inc. (0.28%), SG Americas Securities LLC (0.07%) and AlphaCentric Advisors LLC (0.02%). Insiders that own company stock include Fairmount Funds Management Llc, Jonathan Violin, Scott Dunseth Myers, Lara Meisner, Barrett Katz and Life Sciences Public F Frazier. View institutional ownership trends. How do I buy shares of Viridian Therapeutics? Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRDN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
